Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)

PHASE4CompletedINTERVENTIONAL
Enrollment

1,852

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Mild to Moderate Psoriasis
Interventions
OTHER

TTOP

Patient is taken care of in an intensified, optimised manner

OTHER

non-TTOP

Standard medical care

Trial Locations (93)

Unknown

Herning

Hobro

Roskilde

Vejle

Angers

Auxerre

Brest

Lille

Limeil-Brévannes

Marseille

Martigues

Paris

Poitiers

Saint-Germain-en-Laye

Saint-Mandé

Saint-Priest-en-Jarez

Tours

Vienne

Bad Bentheim

Berlin

Biberach

Blaubeuren Abbey

Bochum

Buchholz

Cologne

Dessau

Frankfurt

Friedrichshafen

Gilching

Hamburg

Hanover

Kiel

Mahlow

Osnabrück

Pinneberg

Selters

Weißenfels

Wolfenbüttel

Wuppertal

Brescia

Catania

Genova

Lucca

L’Aquila

Messina

Padua

Palermo

Parma

Pavia

Perugia

Rome

Trapani

Verona

Amsterdam

Geldrop

Maastricht

Nijmegen

Rotterdam

Alicante

Barcelona

Fuenlabrada (Madrid)

Getafe (Madrid)

Madrid

Palma de Mallorca

Tarragona

Valencia

Zaragoza

Eskilstuna

Gothenburg

Kristianstad

Linköping

Örebrö

Uppsala

Bexhill-on-Sea

Bradford

Burbage

Canterbury

Cheshire

Chesterfield

Coventry

Darwen

East Sussex

London

Manchester

Merseyside

Middlesex

Nantwich

Nuneaton

Oldham

Royal Leamington Spa

Royal Tunbridge Wells

Warwickshire

West Sussex

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Kristian Reich, MD

INDIV

NCT01587755 - Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP) | Biotech Hunter | Biotech Hunter